GT Biopharma (GTBP) Enterprise Value (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Enterprise Value of -$7.1 million for Q1 2026, down 209.38% year-over-year from $6.5 million in Q1 2025, and down 77.62% quarter-over-quarter from -$4.0 million in Q4 2025.
GT Biopharma (GTBP) Enterprise Value (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Enterprise Value for 17 consecutive years, with -$7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 209.38% year-over-year to -$7.1 million; the TTM figure through Mar 2026 stood at -$7.1 million (down 209.38% YoY), while the FY2025 annual figure was -$4.0 million, down 2.59% from the prior year.
- Enterprise Value slipped to -$7.1 million in Q1 2026 per GTBP's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.2 million in Q3 2025 and bottomed at -$29.4 million in Q3 2023.
- Historically, Enterprise Value has averaged -$12.8 million across 5 years, with a median of -$9.7 million in 2024.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 77.83% — and 2026, when it sank 209.38%.
- GT Biopharma's Enterprise Value stood at -$16.5 million in 2022, then climbed by 15.32% to -$14.0 million in 2023, then jumped by 72.15% to -$3.9 million in 2024, then retreated by 2.59% to -$4.0 million in 2025, then plunged by 77.62% to -$7.1 million in 2026.
- Business Quant data shows GTBP's Enterprise Value at -$7.1 million in Q1 2026, -$4.0 million in Q4 2025, and -$2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | -9.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.09 Mn |
| Dec 31, 2025 | -3.99 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -5.32 Mn |
| Mar 31, 2025 | -2.29 Mn |
| Dec 31, 2024 | -3.89 Mn |
| Sep 30, 2024 | -6.51 Mn |
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Dec 31, 2023 | -13.98 Mn |
| Sep 30, 2023 | -29.37 Mn |
| Jun 30, 2023 | -17.97 Mn |
| Mar 31, 2023 | -19.65 Mn |
| Dec 31, 2022 | -16.51 Mn |
| Sep 30, 2022 | -20.77 Mn |
| Jun 30, 2022 | -23.77 Mn |
| Mar 31, 2022 | -26.80 Mn |
| Dec 31, 2021 | -31.98 Mn |
| Sep 30, 2021 | -29.93 Mn |
| Jun 30, 2021 | -39.51 Mn |